Recombinant Human Ephrin B3 protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg2882

---

Validation Data Gallery

• 

  Purity of Recombinant Human Ephrin B3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human Ephrin B3 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human Ephrin B3 protein Leu28-Pro226 (Accession# Q15768) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 1949
• Accession: Q15768
• PredictedSize: 48.0 kDa
• SDS-PAGE: 50-55 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

EFNB3, or ephrin B3, is a member of the ephrin gene family, which encodes a cell surface GPI-bound ligand for the Eph family of tyrosine kinase receptors. EFNB3 is highly expressed in the brain and interacts with GRIP1 and GRIP2, which are key molecules in EFNB reverse signalingEFNB3 is highly expressed in the brain and interacts with GRIP1 and GRIP2, which are key molecules in EFNB reverse signaling. EFNB3 has also been implicated in blood pressure control and vascular smooth muscle cell (VSMC) contractility. Studies have shown that EFNB3 deletion can lead to increased blood pressure in a sex-dependent manner, with vascular smooth muscle being the target tissue mediating this effect (PMID: 26851246).

References:

1. Wang Y. et al. (2016). Am J Physiol Heart Circ Physiol. 310(7):H861-72.